• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24133 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     NIHR Health Technology Assessment programme Patient-reported outcome measures for monitoring primary care patients with depression: the PROMDEP cluster RCT and economic evaluation
2016     HAYES, Inc. Patient-specific instruments for total knee arthroplasty: a review of reviews
2002     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) Patients with low response to controlled ovarian hyperstimulation in assisted human reproduction. Definition, pronostic factors and approach
2000     Israel Center for Technology Assessment in Health Care (ICTAHC) Patients' perceptions of drug therapy counseling in Israel
2002     ECRI Patients' reasons for participation in clinical trials and effect of trial participation on patient outcomes
2015     NIHR Horizon Scanning Centre (NIHR HSC) Patiromer for hyperkalaemia – first line
2020     National Institute for Health and Care Excellence (NICE) Patiromer for treating hyperkalaemia. NICE technology appraisal guidance 623
2019     National Institute for Health and Care Excellence (NICE) Patisiran for treating hereditary transthyretin amyloidosis. NICE highly specialised technologies guidance 10
1998     TNO Pattern recognition: chances and possibilities for the care insurer
2009     NIHR Horizon Scanning Centre (NIHR HSC) Patupilone (EPO906) for recurrent epithelial ovarian cancer - refractory and/or resistant
2008     NIHR Health Technology Assessment programme Payment to healthcare professionals for patient recruitment to trials: systematic review and qualitative study
2012     Institute for Clinical Evaluative Sciences (ICES) Payments to Ontario physicians from ministry of health and long-term care sources, 1992/93 to 2009/10
2008     NIHR Horizon Scanning Centre (NIHR HSC) Pazopanib (GW786034) for advanced and/or metastatic renal cell carcinoma - first/second line
2011     NIHR Horizon Scanning Centre (NIHR HSC) Pazopanib (Votrient) for ovarian, fallopian or peritoneal cancer
2013     NIHR Horizon Scanning Centre (NIHR HSC) Pazopanib (Votrient) for renal cell carcinoma – adjuvant therapy
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pazopanib (Votrient) for the treatment of locally advanced and/or metastatic renal cell carcinoma
2013     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Pazopanib (Votrient®)
2010     NIHR Health Technology Assessment programme Pazopanib for the first line treatment of patients with advanced and/or metastatic renal cell carcinoma: a single technology appraisal
2014     HAYES, Inc. PCA3 detection test for prostate cancer
2009     HAYES, Inc. PCA3 detection test for prostate cancer
2013     Agency for Healthcare Research and Quality (AHRQ) PCA3 testing for the diagnosis and management of prostate cancer
2002     Norwegian Knowledge Centre for the Health Services (NOKC) PCI for acute myocardial infarction
2015     HAYES, Inc. PCSK9 inhibitors for cholesterol reduction: evolocumab
2024     Agency for Care Effectiveness (ACE) PCSK9 inhibitors for treating hypercholesterolaemia
1999     Health Council of the Netherlands Gezondheidsraad (GR) Peak exposures to organic solvents
2006     Agency for Healthcare Research and Quality (AHRQ) Pediatric anthrax: implications for bioterrorism preparedness
2007     HAYES, Inc. Pediatric bariatric surgery for morbid obesity
1999     Health Council of the Netherlands Gezondheidsraad (GR) Pediatric heart transplantation
2008     HAYES, Inc. Pediatric robotic-assisted surgery
2014     The Regional Health Technology Assessment Centre (HTA-centrum) Pediatric robotically assisted surgery for pyeoloplasty and fundoplication
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Pediatric stretchers and stretcher cribs: safety and guidelines
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Pediatric supraglottic airway devices: a review of clinical effectiveness
2004     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) Pediatric tumours of the central nervous system
2014     NIHR Horizon Scanning Centre (NIHR HSC) Pediatric Vision Scanner for the detection of eye conditions in children
2007     Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS) Pedometer and accelerometer in assessing physical activity among children and adolescents
2017     Penn Medicine Center for Evidence-based Practice (CEP) Peer specialists in crisis response centers
2025     NIHR Health Services and Delivery Research programme Peer support for adult social care in prisons in England and Wales: a mixed-methods rapid evaluation
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Peer support for diabetes, heart disease and HIV/AIDS: a review of the clinical effectiveness, cost-effectiveness, and guidelines
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Peer support programs for youth mental health
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Peer support programs for youth mental health
2019     NIHR Health Technology Assessment programme Peer-led walking programme to increase physical activity in inactive 60- to 70-year-olds: Walk with Me pilot RCT
2002     NIHR Horizon Scanning Centre (NIHR HSC) Pegaptanib for age-related macular degeneration - horizon scanning review
2005     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Pegaptanib for neovascular age-related macular degeneration
2010     NIHR Horizon Scanning Centre (NIHR HSC) Pegaptanib sodium (Macugen) for diabetic macular oedema
2015     NIHR Horizon Scanning Centre (NIHR HSC) Pegaspargase (Oncaspar) for acute lymphoblastic leukaemia
2016     National Institute for Health and Care Excellence (NICE) Pegaspargase for treating acute lymphoblastic leukaemia. NICE technology appraisal guidance 408
2022     National Institute for Health and Care Excellence (NICE) Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria. NICE technology appraisal guidance 778
2008     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Pegfilgrastim (Neulasta®) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy
2012     NIHR Horizon Scanning Centre (NIHR HSC) Peginesatide for anaemia in chronic kidney disease – first and second line
2011     NIHR Health Technology Assessment programme Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation
2010     National Institute for Health and Care Excellence (NICE) Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. NICE technology appraisal guidance 200
2006     Quality Improvement Scotland (NHS QIS ) Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
2013     National Institute for Health and Care Excellence (NICE) Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people. NICE technology appraisal guidance 300
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Peginterferon beta-1a (Plegridy®)
2020     National Institute for Health and Care Excellence (NICE) Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 624
2014     NIHR Horizon Scanning Centre (NIHR HSC) Peginterferon lambda-1a for hepatitis C
2016     NIHR Horizon Scanning Centre (NIHR HSC) Pegpleranib (Fovista) for neovascular age-related macular degeneration
2023     National Institute for Health and Care Excellence (NICE) Pegunigalsidase alfa for treating Fabry disease. NICE technology appraisal guidance 915
2016     NIHR Horizon Scanning Centre (NIHR HSC) Pegvaliase for the treatment of hyperphenylalaninaemia in adults with phenylketonuria – first line
2002     NIHR Horizon Scanning Centre (NIHR HSC) Pegvisomant for acromegaly - horizon scanning review
2001     NIHR Horizon Scanning Centre (NIHR HSC) Pegylated interferon alfa for hepatitis C - horizon scanning review
2004     NIHR Health Technology Assessment programme Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation
2007     Canadian Agency for Drugs and Technologies in Health (CADTH) Pegylated interferon combined with ribavirin for chronic hepatitis C virus infection: an economic evaluation
2017     National Institute for Health and Care Excellence (NICE) Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine. NICE technology appraisal guidance 440
2025     National Institute for Health and Care Excellence (NICE) Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal). NICE technology appraisal guidance 1052
2015     NIHR Horizon Scanning Centre (NIHR HSC) Pelareorep (Reolysin) in combination with chemotherapy for metastatic or recurrent squamous cell carcinoma of the head and neck – second line
2015     NIHR Horizon Scanning Centre (NIHR HSC) Pelareorep (Reolysin) with or without chemotherapy for metastatic malignant melanoma – second line
2016     NIHR Horizon Scanning Centre (NIHR HSC) Pelareorep in combination with paclitaxel for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer
2006     HAYES, Inc. Pelvic floor electrical stimulation for the treatment of urinary incontinence
2016     HAYES, Inc. Pelvic floor electrical stimulation for the treatment of urinary incontinence
2024     Ontario Health Pelvic floor muscle training for stress urinary incontinence, fecal incontinence, and pelvic organ prolapse
2024     Ontario Health Pelvic floor muscle training for stress urinary incontinence, fecal incontinence, and pelvic organ prolapse: a health technology assessment
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Pelvic floor repair systems: a review of the clinical-effectiveness, cost- effectiveness, and guidelines
2016     NIHR Horizon Scanning Centre (NIHR HSC) Pembrolizumab (Keytruda) - colorectal cancer: advanced or metastatic; high-level microsatellite instability – second line
2016     NIHR Horizon Scanning Centre (NIHR HSC) Pembrolizumab (Keytruda) - Hodgkin lymphoma: classical; relapsed or refractory – third and fourth line
2015     NIHR Horizon Scanning Centre (NIHR HSC) Pembrolizumab (Keytruda) for advanced or metastatic urothelial cancer – second line
2015     NIHR Horizon Scanning Centre (NIHR HSC) Pembrolizumab (Keytruda) for PD-L1 strong-positive metastatic non-small cell lung cancer – first line
2016     NIHR Horizon Scanning Centre (NIHR HSC) Pembrolizumab (Keytruda) for platinum-resistant, recurrent or metastatic head and neck cancer
2016     HAYES, Inc. Pembrolizumab (Keytruda) for unresectable or metastatic melanoma
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (NSCLC)
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC)
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) for the treatment of advanced melanoma
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer (NSCLC)
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC)
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma. NICE technology appraisal guidance 766
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab for adjuvant treatment of renal cell carcinoma. NICE technology appraisal guidance 830
2025     National Institute for Health and Care Excellence (NICE) Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE technology appraisal guidance 1037
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma. NICE technology appraisal guidance 837
2015     National Institute for Health and Care Excellence (NICE) Pembrolizumab for advanced melanoma not previously treated with ipilimumab. NICE technology appraisal guidance 366
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer. NICE technology appraisal guidance 851
2023     National Institute for Health and Care Excellence (NICE) Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 914
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for the adjuvant treatment of renal cell carcinoma
2016     Institute for Clinical Effectiveness and Health Policy (IECS) Pembrolizumab for the treatment of advanced melanoma
2015     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab. NICE technology appraisal guidance 357
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for treating high-risk early-stage triple-negative breast cancer
2021     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. NICE technology appraisal guidance 692
2025     Agency for Care Effectiveness (ACE) Pembrolizumab for treating locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma
2017     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy. NICE technology appraisal guidance 428
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for treating persistent, recurrent, or metastatic cervical cancer
2019     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 570